Drugs / Anti-COVID-19 human immunoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04395170 | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-COVID-19 human immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04395170 ↗ |
| Known as | IV Anti COVID-19 IgG | “Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG)” NCT04395170 ↗ |
| Modality | Protein / enzyme biologic | “immunoglobulin 10% IgG solution” NCT04395170 ↗ |
| Route | Intravenous | “Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose” NCT04395170 ↗ |